APRINOIA Therapeutics 苏州新旭医药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial 2022-04-11 18:00
APRINOIA Therapeutics Established Collaboration on Tau PET Imaging Tracer Development 2020-12-16 08:00
APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial in China for [18F]-APN-1607 Tau PET Imaging Tracer for Dementia 2020-10-28 14:00
1